Orphelia Pharma

Press Release Lyon, October 8, 2018 Interleukin-17 patent granted in Europe Lyon, France, October 8, 2018 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced the grant of patent EP2569335 by the European Patent Office. This patent covers IL-17A neutralizing antibodies for use as a therapeutic tool to increase the response to other chemotherapeutic agents. “The delivery of this European Patent is another important milestone for OREGA Biotech; it is the fifth issued patent related to our IL‑17 programs”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. “Intellectual property is a key asset in OREGA’s target discovery programs. Our capacity to obtain broad claims covering novel cancer targets offers a valuable competitive advantage.” Read the press release.

On October 23, 2018, Innate Pharma announced that it had entered into a development collaboration and option for further co-development and co-commercialisation with AstraZeneca for its CD39 monoclonal antibody, IPH5201.

Jeremy Bastid, Chief Operating Officer, will attend the 2018 BIO International Convention, to be held in Boston, Massachusetts, June 4-7, 2018.

OREGA will present latest in vivo data of its IL-17B program at the upcoming AACR annual conference to be held in Washington DC. SESSION PO.IM02.06 – Cytokines: The First Modern Immunotherapies April 3, 2017, 8:00 AM – 12:00 PM 1602 / 10 – Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance